Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome

BACKGROUND: Immune-checkpoint blockade (ICB) of programmed-death-1 (PD-1) with pembrolizumab or nivolumab is approved for treating recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). NadiHN and ADRISK are phase IIB trials investigating in locally advanced (LA) HNSCC having low...

Descripción completa

Detalles Bibliográficos
Autores principales: Röhl, Louisa, Wellhausen, Jana, Berszin, Michael, Krücken, Irene, Zebralla, Veit, Pirlich, Markus, Wiegand, Susanne, Dietz, Andreas, Wald, Theresa, Wichmann, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577218/
https://www.ncbi.nlm.nih.gov/pubmed/37849764
http://dx.doi.org/10.3389/fimmu.2023.1237623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577218/
https://www.ncbi.nlm.nih.gov/pubmed/37849764
http://dx.doi.org/10.3389/fimmu.2023.1237623

Ejemplares similares